Navigation Links
SDI Reports: Roughly Half of Patients Prescribed the Most Popular Osteoporosis Drugs Discontinue Therapy Within 6 Months -- Amgen's Prolia Offers New Dosing Option
Date:6/14/2010

According to SDI, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen’s Prolia is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.

(Vocus) June 14, 2010 -- According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen’s Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.

Currently, alendronate, sometimes filled as Fosamax but more frequently as the generic equivalent, is the most popular treatment for osteoporosis. In the 12 months ending April 2010, alendronate accounted for almost 24% of drug issuances for the condition.

Generic alendronate is most often dispensed as a once-weekly therapy. SDI found that 49% of new alendronate patients had discontinued the drug 6 months later. Another 3% had switched to another therapy. After 12 months, 61% of new alendronate patients had discontinued therapy.    

The weekly form of Actonel had similar discontinuation rates. Fifty-four percent of patients taking Actonel once a week had discontinued therapy 6 months after starting; 64% had discontinued after 12 months.

The once-a-month version of Actonel fared slightly better after 6 months with only 47% of patients having discontinued therapy. But at 12 months, 63% had discontinued. The oral form of Boniva, also used once a month, had an even higher percentage of patients discontinuing therapy – 57% after 6 months and 70% after 12.

“Drug adherence is an issue that many in the healthcare industry struggle with, including physicians, pharmacies, and payers. If patients choose to discontinue therapy, they may be at a greater risk for progression of their disease or condition,” said SDI Chief Medical Officer Gregory Hess, M.D., M.B.A.. “There are financial ramifications as well. Using drug therapy to treat osteoporosis is less expensive than treating a patient with a broken bone because they didn’t adhere to therapy.”

About SDI:
SDI is a leading healthcare market insight and analytics firm. It provides the industry’s most comprehensive de-identified patient-level data to pharmaceutical, biotech, and medical device companies, enabling them to better understand the healthcare market. SDI also serves the government and the financial services, media, and consumer packaged goods industries. Founded in 1982, SDI counts the world’s top 50 pharmaceutical and biotech firms as its clients.

###

Read the full story at http://www.prweb.com/releases/2010/SDIosteoporosis/prweb4134214.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. SDI Reports: Pharmaceutical Promotion Spending Indicates Trend Toward Electronic and Online Promotion
2. SDI Reports: Hospital Outpatient Surgical Procedures Increasing, Surgery Centers Growing
3. SDI Reports: Emergency Room Visits Covered by Medicaid Increased 6% in 2009
4. SDI Reports: Nearly a Third Of Physicians Use Handheld and Smartphone Devices to Access Medical Information - Physicians Most Likely to be Using Apple iPhone
5. CNBC Presents 'Tom Brokaw Reports: BOOMER$!' on Thursday, March 4th at 9PM ET/PT
6. SIRIUS XM to Broadcast Doctor Radio Reports: Kids and Video Games - What You Should Know Before You Buy
7. Spinal cord stimulation may benefit Parkinsons patients
8. Brain MRI in children: Incidental findings yield disclosure dilemmas for doctors, patients
9. Study reveals causes of survival disparities based on insurance among rectal cancer patients
10. Uninsured more likely to die from trauma than patients with insurance, study finds
11. Intervention program helps breast cancer patients live longer after recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
SDI Reports: Roughly Half of Patients Prescribed the Most Popular Osteoporosis Drugs Discontinue Therapy Within 6 Months -- Amgen's Prolia Offers New Dosing Option
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
Breaking Medicine Technology: